A mechanistic, model-based approach to safety assessment in clinical development.

J Lippert, M Brosch, O von Kampen, M Meyer, H-U Siegmund, C Schafmayer, T Becker, B Laffert, L Görlitz, S Schreiber, P J Neuvonen, M Niemi, J Hampe, L Kuepfer
Year of publication:
Journal title abbreviated:
CPT Pharmacometrics Syst Pharmacol
Journal title long:
CPT: pharmacometrics & systems pharmacology
Assessing the safety of pharmacotherapies is a primary goal of clinical trials in drug development. The low frequency of relevant side effects, however, often poses a significant challenge for risk assessment. Methodologies allowing robust extrapolation of safety statistics based on preclinical data and information from clinical trials with limited numbers of patients are hence needed to further improve safety and efficacy in the drug development process. Here, we present a generic systems pharmacology approach integrating prior physiological and pharmacological knowledge, preclinical data, and clinical trial results, which allows predicting adverse event rates related to drug exposure. Possible fields of application involve high-risk populations, novel drug candidates, and different dosing scenarios. As an example, the approach is applied to simvastatin and pravastatin and the prediction of myopathy rates in a population with a genotype leading to a significantly increased myopathy risk.CPT: Pharmacometrics & Systems Pharmacology (2012) 1, e13; doi:10.1038/psp.2012.14; advance online publication 7 November 2012.